DISCOVERIES (ISSN 2359-7232), 2018, January-March issue

CITATION: 

Submitted: March 21, 2018; Revised: April 02, 2018; Accepted: April 11, 2018; Published: April 12, 2018;

 GO BACK to 2018, January-March issue

 GO BACK to DISCOVERIES

An update on the diagnosis of growth hormone deficiency

Georgiana Roxana Gabreanu *

Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

*Corresponding author: Georgiana Roxana Gabreanu, MD, Carol Davila University of Medicine and Pharmacy; Email: georgiana.gabreanu@gmail.com

Abstract

Growth hormone deficiency (GHD) is an endocrine disorder, which may be either isolated or associated with other pituitary hormone deficiencies. In children, short stature is a useful clinical marker for GHD. In contrast, symptomatology is not always so obvious in adults, and the existing methods of testing might be inaccurate and imprecise, especially in the lack of a suggestive clinical profile. Since the quality of life of patients diagnosed with GHD could also be significantly affected, in both children and adults, a correct and accurate diagnosis is therefore tremendously important to select those patients that can benefit from the GH treatment. In general, the endocrine diseases are challenging in terms of diagnosis, the simple measurement of the basal level of hormones is not sufficient for distinguishing between the physiological and pathological conditions. Traditionally, several stimulation tests have been considered by professional clinical guidelines, such as insulin tolerance test (ITT), GHRH-arginine stimulation test and the glucagon stimulation test, and all of them have both advantages and limitations. More recently, FDA approved a growth hormone secretagogue receptor agonist, macimorelin, for the diagnosis of adults with GHD (Macrilen, Aeterna Zentaris, Approved: December 2017). The obvious advantage for macimorelin is the simple oral administration and the high level of agreement with the insulin tolerance test for those patients with organic disease and low levels of insulin-like growth factor (IGF-I). However, the safety profile and the diagnostic value was not yet established for the pediatric population and for those adults with extreme or morbid obesity. In addition, administration of macimorelin with drugs that prolong QT interval and CYP3A4 inducers should be avoided. Genetic screening could obviously bring a great insight in the GHD pathology. However, it remains an open question if it would be also cost effective to include it in the routine evaluation of the patients with GHD. Although major progresses have been made in this area, genetic testing continues to be difficult to access, mostly because of its high costs, especially in the low-income and middle-income countries.

Access full text of the manuscript here: Full text (pdf)

References

1. Kato Y, Murakami Y, Sohmiya M, Nishiki M. Regulation of human growth hormone secretion and its disorders. Intern Med. 2002, 41(1):7-13.

2. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML; Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011, 96(6):1587-609.

3. Wacharasindhu S, Cotterill AM, Camacho-Hübner C, Besser GM, Savage MO. Normal growth hormone secretion in growth hormone insufficient children retested after completion of linear growth. ¬¬Clin Endocrinol (Oxf). 1996, 45(5):553-6.

4. Yuen KCJ. Growth hormone Stimulation Tests in Assessing Adult Growth Hormone Deficiency. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, editors. Source Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-2016.

5. Brod M, Pohlman B, Højbjerre L, Adalsteinsson JE, Rasmussen MH. Impact of adult growth hormone deficiency on daily functioning and well-being. BMC Res Notes. 2014, 7: 813.

6. Vyas V, Kumar A, Jain V. Growth Hormone Deficiency in Children: From Suspecting to Diagnosing. Indian Pediatr. 2017, 54(11):955-960.

7. Auernhammer CJ, Reincke M. Functional diagnostics in endocrinology. Internist (Berl). 2018, 59(1):38-47.

8. Cohen P et al. Consensus Statement on the Diagnosis and Treatment of Children with Idiopathic Short Stature: A Summary of the Growth HormoneResearch Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab. 2008, 93(11):4210 – 4217.

9. Mavromati M, Kuhn E, Agostini H, Brailly-Tabard S, Massart C, Piketty ML, Arnoux A, Young J, Souberbielle JC, Chanson P. Classification of Patients with GH Disorders May Vary According to the IGF-I Assay. J Clin Endocrinol Metab. 2017, 102(8):2844-2852 

10. Clemmons DR. Consensus Statement on the Standardization and Evaluation of Growth Hormone and Insulin-like Growth Factor Assays. Clinical Chemestry. 2011. 57:4

11. Nigel Glynn, Amar Agha. Diagnosing Growth Hormone Deficiency in Adults. Int J Endocrinol. 2012, 972617.

12. Yuen KCJ. Growth hormone Stimulation Tests in Assessing Adult Growth Hormone Deficiency. [Updated 2016 Aug 1]. In: De Groot LJ, Chrousos G, Dungan K, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK395585/

13.Yuen KCJ, Chong LE, Rhoads SA. Evaluation of adult growth hormone deficiency: current and future perspectives. [Updated 2013 Feb 28]. In: De Groot LJ, Chrousos G, Dungan K, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. https://www.ncbi.nlm.nih.gov/books/NBK278928/

14. The Endocrine Society. Consensus Guidelines for the Diagnosis and Treatment of Adults with Growth Hormone Deficiency: Summary Statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism. 1998, 83(2):379-81

15. Hartman ML, Crowe BJ, Biller BMK, Ho KKY, Clemmons DR, Chipman JJ, on behalf of the HypoCSS Advisory Board and The U.S. HypoCSS Study Group. Which patients do not require a growth hormone (GH) stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab. 2002, 87:477–485

16. Ho KK. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol. 2007, 157(6):695-700

17. Cook DM, Yuen KC, Biller BM, Kemp SF, Vance ML. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients - 2009 update. Endocr Pract. 2009, 15 Suppl 2:1-29.

18. Sophia Sakka, Angela Casey, Rebecca Follows, Renuka Dias. Comparison of insulin tolerance test to arginine test for the diagnosis of growth hormone deficiency in children. Endocrine Abstracts. 2017. 51. P049

19. US Food and Drug Administration. NDA approval. NDA 205598. https://www.accessdata.fda.gov/ drugsatfda_docs/label/2017/205598s000lbl.pdf December 20, 2017.  Accessed: March 31, 2018.

20. Macrilen (macimorelin) [package insert]. Frankfurt am Main, Germany: Aeterna Zentaris. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205598s000lbl.pdf December 2017. Accessed: March 31, 2018.

21. Kitahara CM et al. Association between class III obesity (BMI of 40-59 kg/m2) and mortality: a pooled analysis of 20 prospective studies. PLoS Med. 2014. 11(7):e1001673.

22. Ortea I, Ruiz-Sánchez I, Cañete R, Caballero-Villarraso J, Cañete MD. Identification of candidate serum biomarkers of childhood-onset growth hormone deficiency using SWATH-MS and feature selection. J Proteomics. 2018, 175:105-113.

23. Cruz-Topete D, Jorgensen JO, Christensen B, Sackmann-Sala L, Krusenstjerna-Hafstrøm T, Jara A, Okada S, Kopchick JJ. Identification of new biomarkers of low-dose GH replacement therapy in GH-deficient patients. J Clin Endocrinol Metab. 2011, 96(7):2089-97. 

24. Cogan JD, Phillips JA. GH1 gene deletions and IGHD type 1A. Pediatr Endocrinol Rev. 2006, 3(Suppl 3):480–488.

25. Mullis PE. Genetics of Isolated Gowth Hormone Deficiency. J Clin Res Pediatr Endocrinol. 2010, 2(2): 52-62.

26. Alatzoglou KS, Turton JP, Kelberman D, Clayton PE, Mehta A, Buchanan C, et al. Expanding the spectrum of mutations in GH1 and GHRHR: genetic screening in a large cohort of patients with congenital isolated growth hormone deficiency. J Clin Endocrinol Metab 2009, 94:3191–3199.

27. Galli-Tsinopoulou A, Kotanidou EP, Kleisarchaki AN, Kauli R, Laron Z. A novel variant c.97C>T of the Growth Hormone Releasing Hormone Receptor gene causes isolated growth hormone deficiency type Ib. J Clin Res Pediatr Endocrinol. 2018.

28. Wit JM, Kiess W, Mullis P. Genetic evaluation of short stature. Best Pract Res Clin Endocrinol Metab. 2011, 25(1):1-17. 

29. Mantovani G, Maghnie M, Weber G, De Menis E, Brunelli V, Cappa M, Loli P, Beck-Peccoz P, Spada A. Growth hormone-releasing hormone resistance in pseudohypoparathyroidism type 1a: new evidence for imprinting of the Gs α gene. J Clin Endocrinol Metab. 2003, 88:4070–4074.

30. Pantel J, Legendre M, Cabrol S, Hilal L, Hajaji Y, Morisset S, Nivot S, Vie-Luton MP, Grouselle D, de Kerdanet M, Kadiri A, Epelbaum J, Le Bouc Y, Amselem S. Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J Clin Invest. 2006, 116:760–768

31. Tommiska J et al. Two missense mutations in KCNQ1 cause pituitary hormone deficiency and maternally inherited gingival fibromatosis. Nat Commun. 2017, 8(1):1289.

32. World Health Organization.  Economic implications of genomics. Cost effectiveness and affordability of genetic services. http://www.who.int/genomics/policy/ affordability/en/   Accessed: April 1, 2018